During the first day of the 44 th Annual JP Morgan Healthcare Conference in San Francisco, a clear narrative emerged. With ...
Biogen's CEO says the company's late-stage pipeline is in good shape, but the drugmaker is still hunting for deals to build ...
Three years after the accelerated approval of its anti-amyloid Alzheimer’s therapy, Biogen—neck and neck in the market with ...
Biogen Inc.’s new at-home Alzheimer’s drug will give the company an edge over rival Eli Lilly Co.’s competing therapy, its ...
Venture investors are adopting a more aggressive mindset heading into 2026, while Merck, Moderna and Summit are all ...
SA Rugby has revealed that wellness company Biogen is a new brand partner after signing a three-year sponsorship ...
Proximity Health Solutions and Biogen Named Finalists for the SCOPE '26 Participant Engagement Award
Proximity Health Solutions, in collaboration with Biogen, announces that Better Together: Sharing Our Lupus Stories has been selected as one of the four finalists for the prestigious 2026 SCOPE ...
Barchart on MSN
What to expect from Biogen's next quarterly earnings report
Cambridge, Massachusetts-based Biogen Inc. (BIIB) discovers, develops, manufactures, and delivers therapies for treating ...
Piper Sandler analyst David Amsellem reiterated a Hold rating on Biogen today and set a price target of $157.00. Claim 50% Off TipRanks Premium. Unlock hedge fund-level data and p ...
US biotech Biogen (Nasdaq: BIIB) said the European Commission on January 12, 2026 granted marketing authorization for a ...
Biogen Inc. (NASDAQ:BIIB) is one of the best performing pharma stocks in 2025. Biogen Inc. (NASDAQ:BIIB) received several ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback